drugset / Trial / NCT03389230
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
Phase 1
Active not recruiting
29 enrolled
City of Hope Medical Center
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of memory-enriched T cells in treating patients with grade II-IV glioma that has come back (recurrent) or does not respond to treatment (refractory). Memory enriched T cells such as HER2(EQ)BBζ/CD19t+ T cells may enter and express its genes in immune cells. Immune cells can be engineered to kill glioma cells in the laboratory by inserting a piece of deoxyribonucleic acid (DNA) into the immune cells that allows them to recognize glioma cells. A vector called lentivirus is used to carry the piece of DNA into the immune cell. It is not known whether these immune cells will kill glioma tumor cells when given to patients.
Timeline
- Start
- 2018-08-14
- Primary completion
- 2026-12-29
- Completion
- 2026-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HER2(EQ)BBζ/CD19t+ T cells | Cell therapy | — | Other |